Autoantibodies against interleukin (IL) -17A, IL-17F and IL-22 have recently been described in patients with autoimmune polyendocrine syndrome type I (APS I), and their presence is reported to be highly correlated to chronic mucocutaneous candidiasis (CMC). The aim of the present study was to develop a robust high-throughput radioligand binding assays (RLBA) measuring IL-17F and IL-22 antibodies, and to compare them with current enzyme-linked immunosorbent assays (ELISA) of IL-17F and IL-22; moreover to correlate the presence of these antibodies to the presence of CMC. Interleukins are small molecules which make them difficult to express in vitro. To overcome this problem, they were fused as dimers, which proved to increase the efficiency of expression. A total of five RLBAs were developed based on IL-17F and IL-22 monomers and homo-or hetero dimers. Analysing the presence of these autoantibodies in 25 Norwegian APS I-patients revealed that the different RLBAs detected anti-IL-17F and anti-IL-22 with high specificity, using both homo-or heterodimers. The RLBAs based on dimer proteins are highly reproducible with low inter-and intra-variation, and have the advantages of high throughput and easily standardisation compared to ELISA, thus proving excellent choices for the screening of IL-17F and IL-22 autoantibodies.
Introduction
The majority of patients with autoimmune polyendocrine syndrome (APS I) develop at least two of the three main components autoimmune adrenocortical failure (Addison's disease), hypoparathyroidism [1] , and chronic mucocutaneous candidiasis (CMC) [2, 3] . The underlying cause is mutations in the autoimmune regulator (AIRE) gene, inherited in an autosomal recessive manner [4] [5] [6] . AIRE is mainly expressed in the thymic medullary epithelial cells where it orchestrates transcription of tissue-specific proteins for presentation to developing T cells [7] [8] [9] [10] [11] [12] . Without a functional AIRE, autoreactive T cells are allowed to escape into the periphery where they later on may be activated and give rise to organ-specific autoimmune diseases.
Until recently, the strong propensity for CMC in APS I has remained an enigma. The recent discovery of high frequencies of IL-17A, IL-17F and IL-22 autoantibodies in sera of APS I patients implies that autoantibody-mediated inhibition of crucial elements in the defence against C. albicans may cause these infections [13, 14] . IL-17F is essential in host defence against extracellular bacteria and fungi, by inducing production of cytokines, chemokines and hematopoetic factors [15, 16] . IL-22 belong to a class of cytokines with a predominant effect on epithelial cells and provides protection on all outer barriers by directly stimulate innate immune responses [17] . Both IL-17F and IL-22 are active as homodimers, and IL-17F also bind to its receptor as a heterodimer with IL-17A [15, 18, 19] .
Th17-expressed cytokines have previously been reported to be up-regulated in several autoimmune diseases [16] , in contrast to patients with isolated hereditary CMC, in whom they are down-regulated [20] [21] . Studies using peripheral blood mononuclear cells from APS I patients differs in their results regarding the Th17 response towards C. albicans. One study claims that the IL-17A response is up-regulated while the IL-22 response is down-regulated [22] , in contrast to the previous report of unaltered IL-17A and decreased IL-17F and IL-22
Autoantibodies against IL-17F and IL-22 are prevalent in APS I, and may be used as a biomarker of the disease itself and of the presence of CMC. As the frequency of anti-IL-17A previously has been reported to be quite low in APS I patients [13], we aimed to develop reliable assays to measure autoantibodies against IL-17F and IL-22.
Material and Methods

Subjects and serum samples
This study included sera from 25 Norwegian APS I patients (mean age 36.1 years, 9 females and 16 males, 21 of 25 diagnosed with CMC). Clinical phenotype and mutational status have been described previously for most of the patients [6] . In addition, 67 healthy blood donors (anonymous, unknown mean age and gender) recruited from Haukeland University Hospital Blood Bank were used as controls to ensure that the range of the assays were satisfying, and to validate individual results between assays. The study was approved by the local ethical committee and all participating patients signed an informed consent before participation.
Expression and subcloning of IL-17F, IL-22, IL-17F:IL-17F, IL-22:IL-22, and IL-17F:IL-22
IL-17F and IL-22 were expressed directly from the pCMV-vector (OriGene, Rockville, MD, US). To synthesize dimers and chimeric proteins, human IL-17F and IL-22 cDNAs in the pDEST15 vector (Invitrogen, Carlsbad, CA, US) were used as PCR templates with primers introducing new restriction-sites (Table 1) . The 5' end of the first part of the fusion-protein cDNA was inserted into the vector, using primers with a mutated stop-codon. The procedure was then repeated with the second cDNA, using primers with the original stop-codon (Table   1) . Amplified PCR-products were extracted using a PCR-cleanup kit (Qiagen, Valencia, CA, US). The PCR-products and the recipient plasmid pcDNA3 (Invitrogen) were then incubated with 10 units (U) of NotI and/or XhoI and BamHI, all in buffer D (Promega, Madison, WI, US) in a total volume of 40 μl at 37 °C for four hours. After electrophoresis using a 1% low melting point agarose gel, the products were excised and melted at 70°C for 10 minutes, and used directly in a in-gel ligation reaction consisting of extracted pcDNA3 (1 μl) and digested and extracted PCR-products (3 μl). The ligation reactions were incubated overnight with 10 U T4 ligase and 10 x ligase buffer (New England Laboratories, Ipswich, MA, US) in a total volume of 30 μl at room temperature. The ligase-solutions were subsequently melted at 70°C for 10 minutes and 3 μl transfected into one-shot TOP10 competent cells (Invitrogen) according to the manufacturer's protocol. The constructs used for protein expression of all products were verified by sequencing to ensure no mismatch in the open reading frame.
Radioligand binding assay (RLBA) of anti-interleukins antibodies
Sera were analysed for antibodies against IL-17F, IL-22, IL-17F:IL-17-F, IL-22:IL-22 and IL-17F:IL-22 using in vitro transcribed and translated radiolabelled proteins essentially as described by Husebye et al [23] . Each sample was tested in duplicate (about 30 000 cpm radiolabelled protein per well), and the results expressed as index [(cpm sample -cpm negative control / cpm positive control -cpm negative control) x 1000]. Pooled human sera from healthy donors was used as negative control, and an APS I serum with high antibody titer was used as positive control. Two APS I sera were tested three times in order to calculate inter-and intra-assay variability, expressed as coefficient of variation (CV) (CV (%) = (SD / mean)*100). Intra-variability ranged from 1.3 -6.4% for all assays, and inter-variability from 5.1 -8.1%, with the exception of the IL-17F monomer assay (35.1%). Sera from 50 and 67 healthy controls were used to set the normal limit for the monomer and dimer assays, respectively (index mean of blood donors + 3 SD).
To investigate the specificity of the assays, non-radioactive IL-17F, IL-22, and ovalbumin 
SDS-PAGE
To ensure proper expression of the proteins, approximately 200 000 cpm of the five proteins were separated on a 10 % Nu Page Bis-Tris gel (Invitrogen) and calibrated with SeeBlue PreStained Standard (Invitrogen). The gel was dried, exposed overnight on an imaging plate, and labelled protein bands visualised using Fujifilm BAS-2500 phosphoimager (Fuji Medical Systems, Stamford, CO, USA).
ELISA
Nunc maxi sorb immunosorbent 96-well flat-bottomed plates were coated with 100 μL/well of IL-17F or IL-22 (R&D Systems, Minneapolis, MN, US) with at total of 0.1 μg/ml protein for each well, diluted in PBS and incubated at 4°C overnight. After removing excess antigens by decanting, non-specific binding sites were blocked for 30 minutes at 37°C with 100 μL PBS with 0.1% Tween-20 (P7949 Sigma-Aldrich) and 3% bovine serum albumin (BSA) (A7030 Sigma-Aldrich). Plates were then washed four times with washing buffer (PBS w/ 0.1% Tween-20) and 100 μL patient or blood donor serum samples diluted 1:50 in blocking buffer were added in duplicates to each well and incubated one hour at room temperature with shaking. The plates were washed four more times and alkaline phosphatise conjugated goat anti-human IgG (diluted 1:2000 in blocking buffer) (A3187-1ML, Sigma-Aldrich) was added, followed by a new one hour incubation at room temperature with shaking. After five final washes, anti-protein binding was visualized by adding SIGMAFAST p-nitrophenol phosphate substrate solution according to the manufacturer's protocol (Sigma-Aldrich) and absorbance at 405 nm was read after 20 minutes incubation in the dark using a Tecan spectrophotometer (Männedorf, Switzerland). Intra-and inter-variability was 2.9 % and 7.7 % for IL-17F and 1.6 % and 2.4 % for IL-22, calculated as described for the RLBAs.
Statistical Analysis
Correlations between RLBA and ELISA were calculated using the Spearman r test, confidence interval and p-value (Graphpad version 5.02). Overall, all RLBAs were reliable in autoantibody detection, illustrated by the trend in antibody-titer for each patient analysed against the different antigens (Fig. 2) . The antibody indices for IL-22 were in general higher then those of IL-17F, while the fusion-protein of IL-17F and IL-22 gave intermediate index values, reflecting the dual recognition (Fig. 2) .
Results
Radioimmunoassays (RLBAs)
SDS
Specificity of the autoantibody detection
To ensure a highly specific autoantibody-detection in all RLBAs, non-radioactive IL-17F or IL-22 were added at different concentrations, together with a patient serum positive for both anti-IL-17F and anti-IL-22 before addition of the corresponding radioactive protein. Full blocking was observed for all assays, while the negative control using ovalbumin did not interfere with antigen-antibody binding (Fig. 3. A-D) . In the chimeric assay, addition of either IL-17F or IL-22 gave approximately 50 % reduction in antibody index, while the combination of the two gave full reduction (Fig. 3E) . Using a serum positive exclusively for anti-IL-22, full inhibition was obtained adding non-radioactive IL-22, alone or in combination with IL-17F, while no reduction was observed for the competition with only non-radioactive IL-17F (Fig. 3F) .
RLBA correlates to ELISA and to previous studies
Forty-eight percent of the patients were positive for anti-IL-17F as measured by ELISA, compared to 36% when the same patient sera were analysed by RLBA (Fig. 4A) . The opposite was the case for anti-IL-22, with a higher detection-rate in RLBA (80 %) compared to 72 % in ELISA (Fig. 4B ). Despite these differences, the correlation between the different RLBAs (index-values) and the ELISAs (A 405 ) were still satisfying, described by Spearman's r, confidence interval and p-values (Table 2) .
Autoantibodies against IL-17F, IL-22 and chronic mucocutanous candidiasis
Previously, an almost perfect correlation between anti-IL-17F and anti-IL-22 and CMC has been described [13, 14] . Two patients (siblings) included in this study, both of whom had clinically evident CMC at the time of sampling, lacked both anti-IL-17F and anti-IL-22
antibodies. Moreover, three of the four patients included in this study without CMC had autoantibodies against IL-22. Taken together, the sensitivities of anti-IL-17F to detect previous episodes or ongoing clinically evident CMC was up to 70%, while the sensitivities approached 100% in the different assays (see Table 3 for details). Using anti-IL-22, sensitivities were 70-80 %, but specificities were low; around 25% (Table 3) . Some uncertainty remains as candidiasis in the oesophagus may not have been detected in all cases.
Discussion
We have here shown that RLBAs based on IL-17F and IL-22 as monomers or dimers are highly specific in their antigen-detection, and discriminate well between positive and negative samples. Dimeric expression enhances incorporation of radioactivity more than the addition of methionine groups, and makes them less susceptible of degradation by the ubiquitin pathway. The increased size may also give a better refolding of the proteins [24] . The heterodimer introduces the possibility of detecting both antibodies in one assay, although without the possibility of discrimination. It also has the advantages of low analysis time, decreased cost and limited amount of patient-material required.
In general, the performance of ELISA varies widely, especially when used for autoantibody detection. ELISA requires more sample-material, is more costly, and has a lower sensitivity and specificity compared to RLBA [25, 26] . Here, using both methods on the same patientmaterial, we revealed discrepancies; mainly that ELISA gave a higher number 
